Facts
- Metoclopramide is the generic equivalent of the brand-name drug Reglan.
- Federal law requires generic-drug labeling to be the same as the corresponding brand-name labeling.
- Danny Weeks was prescribed and ingested only generic metoclopramide for an extended period and alleged he developed tardive dyskinesia and related injuries.
- Weeks alleged brand-name manufacturers knew long-term use posed a substantially higher risk of severe neurological side effects than their labeling disclosed.
- Weeks and his wife sued brand-name manufacturers, asserting Alabama tort claims including fraudulent misrepresentation, fraudulent suppression, negligent misrepresentation, and misrepresentation-based failure-to-warn theories.
- Weeks conceded the brand-name defendants did not manufacture or sell the pills he ingested.
- The federal district court certified to the Alabama Supreme Court whether Alabama law permits misrepresentation-based liability against a brand-name manufacturer when the plaintiff consumed only a generic made by another company.
Issues
- Whether, under Alabama law, a brand-name drug manufacturer may owe a duty supporting fraud or misrepresentation claims to a plaintiff injured by ingesting only the generic equivalent made by another manufacturer.
- Whether the absence of product identity (the defendant did not make or sell the ingested product) categorically bars misrepresentation-based failure-to-warn claims.
- Whether foreseeability of prescribing-physician reliance on brand-name labeling, given the federal “same labeling” requirement, can support duty and proximate causation.
Decision
- The Alabama Supreme Court answered the certified question “Yes.”
- A brand-name manufacturer may be subject to fraudulent misrepresentation, fraudulent suppression, negligent misrepresentation, and related misrepresentation-based failure-to-warn theories even when the plaintiff ingested only the generic equivalent.
- The Court emphasized the ruling concerns misrepresentation-based theories tied to warnings and labeling, not strict products-liability claims for a defective product.
- The Court grounded duty in the brand-name manufacturer’s role as originator of labeling that generic manufacturers must copy and in the foreseeability that physicians will rely on that information when prescribing generics.
- The matter returned to federal court for further proceedings without dismissal solely on the ground that the defendants did not manufacture the product ingested.
Legal Principles
- In misrepresentation-based warning cases, duty may arise from a manufacturer’s superior knowledge and its obligation to communicate risk information, not from having made the specific unit of product ingested.
- Because generic labeling must match brand-name labeling, it is reasonably foreseeable that prescribing physicians will rely on brand-name warnings and representations when prescribing the generic equivalent.
- Alabama law does not impose a categorical bar to liability in misrepresentation claims merely because the defendant did not manufacture or sell the injurious product, where alleged misstatements or omissions foreseeably induce third-party reliance that proximately causes injury.
- The learned intermediary doctrine supports focusing on whether the prescribing physician relied on the challenged labeling and warnings.
- Plaintiffs must still prove the traditional elements of the asserted torts (including reliance and causation); the decision addresses only whether a duty and potential liability can exist on these facts.
Conclusion
The Alabama Supreme Court held that brand-name drug manufacturers can face misrepresentation-based claims for allegedly inadequate warnings and labeling by plaintiffs injured from ingesting only the generic equivalent, where it is foreseeable that a prescribing physician would rely on the brand-name labeling that generic manufacturers are required to duplicate.